A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Becerra, CR
  • Takimoto, C
  • Ajani, JA
  • Major, Pierre
  • Feit, K
  • Duggal, A
  • De Jagger, R

publication date

  • July 15, 2004